Systemic therapy has historically been the backbone of treatment for patients with metastatic disease. However, recent evidence suggests metastasis-directed therapy in those with oligometastatic disease (≤5 lesions) may improve progression-free and overall survival. Within prostate cancer-specific cohorts, metastasis-directed therapy also appears to delay the time to initiation of androgen deprivation therapy while also generally being associated with a mild toxicity profile and has thus garnered interest as a means to delay systemic therapy. Here we review the evidence surrounding the use of radiation therapy to metastatic sites in patients with metastatic hormone-sensitive prostate cancer.

中文翻译：

---

放射治疗转移性激素敏感性前列腺癌的治疗标准是什么？

历史上，全身治疗一直是转移性疾病患者治疗的骨干。但是，最近的证据表明，针对转移性肿瘤（≤5个病变）的患者进行转移导向治疗可能会改善无进展生存期和总体生存率。在前列腺癌特异性人群中，转移导向治疗似乎也延迟了雄激素剥夺治疗的开始时间，同时通常还与轻度毒性反应有关，因此引起人们的兴趣作为延迟全身治疗的手段。在这里，我们回顾了对转移性激素敏感性前列腺癌患者的转移部位使用放射治疗的证据。